ArticleCureus2025
Can the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Index Be Used as a Prognostic Marker in Patients Diagnosed With Idiopathic Pulmonary Fibrosis?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe hemoglobin-albumin-lymphocyte-platelet (HALP) score serves as an indicator of systemic inflammation and can be utilized as a prognostic marker. It has been previously associated with many cancers, but its relationship with prognosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF) is unknown. In our study, we aimed to evaluate the usability of the HALP score as a prognostic marker in patients diagnosed with IPF.
methodsThe study evaluated patients with IPF who were diagnosed and had follow-up visits in the pulmonary medicine clinic of a tertiary hospital between January 2021 and March 2023. Patients' clinical information, comorbidities, laboratory values, pulmonary function test-diffusion capacity of the lung for carbon monoxide (PFT-DLCO) parameters at the time of diagnosis, six-minute walk tests, body mass indices, prognosis information, and death information were recorded.
resultsA total of 224 patients were included in the study, with a mean age of 66.27 (±8.83) years and a predominantly male population (84%). The mean HALP score was 53.27 (±27.73), and with a cut-off of 25 for HALP, survival duration of patients between groups were statistically; a median survival of 493 (40-945) days for patients with a score of 25 or below for HALP and 981 (752-1209) days for those above it (log-rank test result of 0.01 and X
conclusionThe HALP score is a reliable, simple, easily accessible, and inexpensive index for predicting the prognosis of IPF. Further studies are required to evaluate subgroup outcomes for IPF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.